Poster Presentation Details: Title: NLC-V (Tollovir™) as an Adjunctive Therapy in Hospitalized Patients Diagnosed with COVID-19: A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial ...

Paxlovid 2.0: Next generation of COVID antiviral hits final human trials By Rich Haridy March 18, 2025 The next generation of COVID antiviral promises to be safer, easier to dose, with fewer side ...

Source Reference: Gao Y, et al "Antiviral medications for treatment of nonsevere influenza: a systematic review and network meta-analysis" JAMA Intern Med 2025; DOI: 10.1001/jamainternmed.2024.7193.

Study findings also saw almost 37% of hospitalized infants younger than 6 months old, who are not eligible for flu vaccination, did not receive an antiviral. "The low use of influenza antivirals ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. The study saw 114 healthy adults inoculated with the virus and ...

Enanta Pharmaceuticals’ respiratory syncytial virus (RSV) antiviral reduced the viral load in a phase 2 study in children, maintaining hopes the biotech can find a niche in a market now ...

Poster Presentation Details: Title: NLC-V (Tollovir™) as an Adjunctive Therapy in Hospitalized Patients Diagnosed with COVID-19: A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial ...